Adrienne M. Gilligan

Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants

Abstract Objectives: Compare costs and healthcare resource utilization (HCRU) among newly-diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs apixaban, rivaroxaban, or warfarin. Methods: Newly-diagnosed adult NVAF patients initiating dabigatran, apixaban, rivaroxaban, or warfarin (index event) between October 1, 2010–December 31, 2014 were identified using MarketScan claims data, and followed until medication discontinuation, switch, inpatient death, enrollment end, or study end (December 31, 2015). Dabigatran patients were propensity-score matched 1:1 separately with apixaban, rivaroxaban, and warfarin patients. Per-patient-per-month (PPPM) all-cause cost, HCRU, and 30-day re-admissions were reported. Costs were analyzed using generalized linear models. Results: Final cohorts, each matched with dabigatran patients, included 8,857 apixaban patients, 26,592 rivaroxaban patients, and 33,046 warfarin patients. Dabigatran patients had lower adjusted PPPM total healthcare, inpatient, and outpatient costs compared to rivaroxaban (

Comparison of All-Cause, Stroke, and Bleed-Specific Healthcare Resource Utilization among Patients with Non-Valvular Atrial Fibrillation (NVAF) and Newly Treated with Dabigatran or Warfarin

4,093 vs

Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin

4,636,

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.

1,476 vs

Comparative cost and clinical effectiveness of clostridial collagenase ointment for chronic dermal ulcers

1,862, and

Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine

2,016 vs

Healthcare resource utilization (HRU) and costs associated with renal impairment (RI) among treated multiple myeloma (MM) patients.

2,121, respectively, all p ≤ .001) and warfarin (

Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat

4,199 vs

Abstract 277: Comparison of All-Cause Hospitalization Rates and 30-Day Readmissions Among Patients With Non-Valvular Atrial Fibrillation, Newly Diagnosed and Newly Treated With Dabigatran, Rivaroxaban or Warfarin

4,872,

Hospital admissions (HA) among chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients newly treated with enzalutamide (ENZA) or abiraterone (ABI).

1,505 vs